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ABSTRACT: Introduction: Amyotrophic lateral sclerosis (ALS)
is a progressive disease caused by the degeneration of upper
and lower motor neurons. The etiology of ALS is unclear, but
there is evidence that loss of cortical inhibition could be related
to motor neuron degeneration. We sought to determine whether
cathodal transcranial direct current stimulation (tDCS) can
reduce cortical excitability in patients with ALS. Methods: Three
sessions of cathodal tDCS, lasting 7, 11, or 15 minutes, were
performed in 10 patients and 10 healthy controls. Corticospinal
excitability was measured before and after the tDCS.
Results: Cathodal tDCS induced a consistent decrease in cor-
ticospinal excitability in healthy controls, but not in ALS patients.
Conclusions: The failure of tDCS to produce an excitability
shift in the patients supports the potential diagnostic value of
tDCS as a marker of upper motor neuron involvement. How-
ever, variation in corticospinal excitability measurements both
inter- and intraindividually will limit its usefulness.
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Amyotrophic lateral sclerosis (ALS) is a progres-
sive and fatal neurodegenerative disease caused by
the degeneration of both the upper and lower
motor neurons that control voluntary muscle
movement. Although the exact etiology of ALS is
unclear, loss of inhibition in motor cortex circuits
has been described in patients with ALS, particu-
larly early in the disease.1 It is speculated that
loss of inhibition not only causes central motor
neuron loss but also drives anterior horn cells into
metabolic deﬁcit, a process called anterograde
degeneration.2
A decade ago, a non-invasive tool to modulate
cortical excitability, transcranial direct current
stimulation (tDCS), was reintroduced.3 With tDCS,
a weak constant electrical current (1 mA), which
passes through the skull and underlying structures
to the cortical structures, up- or downregulates
cortical excitability depending on the stimulation
polarity used. Cathodal tDCS over the motor cor-
tex, where the cathode is placed over the primary
motor cortex and the anode above the contralat-
eral eyebrow, leads to decreased excitability of the
motor cortex in healthy controls, evidenced by
decreased muscle responses elicited by transcranial
magnetic stimulation (TMS).4–17 If tDCS is applied
for several minutes, the changes can outlast the
stimulation by up to 1 hour.11,18 Given cortical dis-
inhibition in patients with ALS, cathodal tDCS is
considered a proposed treatment option. In
healthy subjects, stimulation for at least 3 minutes
at 1 mA already elicits an after-effect.10 Stimulation
for up to 15 minutes at 1 mA is without noticeable
side effects.19 Thus, stimulation for 3–15 minutes
appears to be safe and effective.
Only one study has investigated the effects of
tDCS stimulation in patients with ALS.6 Anodal
and cathodal tDCS, performed for 7 minutes, led
to a consistent modiﬁcation of cortical excitability
in healthy subjects, but not in patients with ALS.
However, in this study the duration of tDCS stimu-
lation was not varied, even though studies of
healthy individuals have shown that the duration
of stimulation inﬂuences the extent and duration
of cortical modulation.11,18 The investigators sug-
gested that tDCS might be useful as a diagnostic
tool for ALS. They did not discuss the potential of
tDCS as a therapeutic strategy. Obviously, to have a
therapeutic effect on the continuous process of an-
terograde degeneration, cortical modulation needs
to be present, but it also must be long-lasting.
The ﬁrst aim of our study was to address the
potential of tDCS as a therapeutic strategy. The
second aim was to further investigate the diagnos-
tic potential of short-duration tDCS, as reported by
Quartarone et al.6 For this purpose, we studied the
effect of lengthening the tDCS stimulation up to
15 minutes in an attempt to induce lasting changes
in cortical excitability.
METHODS
Subjects. Ten patients with sporadic ALS and 10
healthy controls participated in this study. All
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patients were categorized as having clinically prob-
able ALS according to the revised El Escorial crite-
ria.20 In all patients and controls we were able to
consistently elicit MEPs in the contralateral target
muscle with a mean peak-to-peak amplitude of at
least 1 mV. At the time of the study all patients
were on riluzole. The patients were recruited from
the National ALS Center. The controls were
recruited through posters and ﬂyers displayed at
the Radboud University Nijmegen Medical Center.
All patients and controls gave written informed
consent prior to inclusion in the study. The study
was approved by the ethics committee of the Rad-
boud University Nijmegen Medical Center and was
performed in accordance with the ethics standards
established by the Declaration of Helsinki.
Transcranial Direct Current Stimulation. The study
protocol consisted of three experimental sessions
separated by 1 week. In each session, participants
received cathodal tDCS (1 mA) for either 7, 11, or
15 minutes (in random order). We did not use
anodal tDCS, because only cathodal tDCS is
expected to be potentially effective in patients with
ALS. tDCS was delivered using a constant-current
stimulator (Eldith, NeuroConn GmbH, Ilmenau,
Germany) via two conductive rubber electrodes
(35 cm2) inside saline-soaked sponges placed on
the scalp. The cathode was placed over the left pri-
mary motor hand area and the anode above the
right eyebrow. Before the electrodes were placed,
the skin was rigorously cleaned and lightly abraded
to reduce impedance. The target skin impedance,
as measured by the stimulator, was <15 kX. To
avoid abrupt sensations, the stimulation period was
initiated by a fade-in period (10 seconds) and com-
pleted by a fade-out period (10 seconds).
Transcranial Magnetic Stimulation. We used various
well-established TMS paradigms21 to compare corti-
cospinal excitability of the stimulated left primary
motor hand area before (baseline, 0) and 5 and 20
minutes after tDCS. All TMS measurements were
performed using two monophasic magnetic stimu-
lators (Magstim 2002; Magstim Co., Whitland,
Wales, UK), which were connected through a user
interface module (BiStim2) to a standard circular
coil (diameter 90 mm, Magstim) centered above
the vertex with the A-side visible. Each stimulus
induces an anticlockwise current, resulting in poste-
rior–anterior current ﬂow in the left hemisphere.
Because of non-focal stimulation with tDCS, we
measured excitability with a round non-focal coil.
Several measures of corticospinal excitability were
assessed with single- and paired-pulse TMS.
(i) Stimulus intensity needed to evoke a motor-evoked
potential of 0.5-mV amplitude (SI0.5mV). SI0.5mV was
deﬁned as the lowest stimulator output intensity at
which a single TMS pulse induced motor-evoked
potentials (MEPs) of at least 0.5-mV peak-to-peak
amplitude in the right abductor digiti minimi
(ADM) muscle in at least 5 of 10 trials. We used
this measure instead of the resting motor thresh-
old (criterion of 50 lV), because patients often
had fasciculations in their hand muscles. The pres-
ence of fasciculations rendered it impossible to dis-
tinguish between small MEPs and spontaneous fas-
ciculations when TMS was given around threshold
intensity.
(ii) Single-pulse MEPs. Before tDCS, the lowest
stimulator output intensity needed to induce MEPs
with a mean amplitude of approximately 1 mV
(SI1mV) was determined from, on average, 20 con-
secutive trials. This intensity was used to deliver 30
consecutive pulses at, on average, 0.25 Hz (random
4-, 5-, and 6-second intervals).
(iii) Paired-pulse TMS was performed for each
subject to investigate short-interval intracortical in-
hibition and facilitation (SICI and ICF, respec-
tively).22 The conditioning subthreshold stimulus
was set to 80% of the SI0.5mV and was delivered
through the same magnetic coil at interstimulus
intervals of 2–3 ms to assess SICI, and 10 and 12
ms to assess ICF before a suprathreshold test stim-
ulus. The test stimulus intensity was set to SI1mV
and was kept constant throughout the experiment.
This procedure allows the measurement of intra-
cortical inhibition and facilitation, which are con-
sidered to reﬂect the excitability of short inhibitory
and facilitatory interneuronal circuits in the motor
cortex.23 A randomized protocol was run to mea-
sure SICI and ICF. It consisted of 50 stimuli given
at, on average, 0.25 Hz in blocks of 10 stimuli.
Forty conditioned MEPs were recorded (10 for
each ISI) and 10 unconditioned MEPs.
Procedure. During each session, the participants
were seated in a slightly reclining chair with the
elbow semiﬂexed and the forearm supinated, fully
relaxed, and supported by a pillow on the thigh.
Prior to the TMS baseline measurements, com-
pound muscle action potentials (CMAPs) were
measured in the ADM and the abductor pollicis
brevis (APB) muscles of the right hand through
supramaximal peripheral stimulation of the ulnar
and median nerve (6 cm proximal to the active
electrodes), respectively. Stimulation was done
using a constant-current stimulator (Model DS7A;
Digitimer, Ltd., Welwyn Garden City, UK).
We used visual electromyographic (EMG) feed-
back to be sure of complete relaxation of the ADM
muscle. No feedback was given for the other hand
muscles. We chose the ADM muscle because other
commonly used muscles, such as the ﬁrst dorsal
interosseus muscle and APB, are the most atrophic
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in patients with ALS (split hand24,25), which makes
it more difﬁcult to evoke consistent MEPs in those
muscles. Obtaining the excitability measures took,
on average, 10 minutes, and one complete session
took 65 minutes.
Data Acquisition. Surface EMG activity of the ADM
muscle was recorded using self-adhesive Ag–AgCl
surface electrodes (Soft-E H69P; Kendall-LTP,
Chicopee, Massachusetts) using a belly–tendon
montage. EMG signals were ampliﬁed (0.6 lV/bit)
and bandpass ﬁltered between 10 and 500 Hz. The
EMG signals were acquired at a rate of 10 kHz
(CED 1401 Laboratory Interface; Cambridge Elec-
tronic Design, Cambridge, UK) and recorded
using Spike2 software (Cambridge). Digitized
recordings, running from 500 ms before to 1500
ms after each TMS trigger, were stored for further
analysis.
Analysis. For each block of measurements [base-
line (0), 5 and 20 minutes after tDCS], the peak-
to-peak amplitude of each MEP (in millivolts) was
measured off-line, and the mean MEP amplitude
was calculated for each stimulation condition (sin-
gle-pulse MEP, SICI, and ICF) with custom-written
MatLab (The MathWorks, Inc., Natick, Massachu-
setts) software scripts. To compare the responses
of the individuals, the baseline values of SI0.5mV
and single-pulse MEPs were set to 100%, and for
the follow-up measurements the relative change
was calculated.
For SICI and ICF, the ratio between the condi-
tioned MEP and the unconditioned MEP was cal-
culated from individual data. The SICI was calcu-
lated as the mean of ISI 2 ms and 3 ms, and ICF
as the mean of ISI 10 ms and 12 ms. Ratios <1
indicate inhibition, whereas ratios >1 indicate
facilitation.
Stimulus intensities and MEP amplitudes for
the different excitability measures were entered
separately in three-way repeated-measures analyses
of variance (ANOVAs) with tDCS duration (7, 11,
and 15 minutes) and time [baseline (0), 5, and 20
minutes after tDCS] as within-subject factor and
group (patients or controls) as between-subjects fac-
tor. The Greenhouse–Geisser method was used in
case of non-sphericity. If the F-value was signiﬁcant,
paired-sample, two-tailed t-tests were used for post
hoc comparisons. For all tests, P  0.05 was consid-
ered signiﬁcant. Data are given as mean 6 standard
error of the mean, unless otherwise indicated.
RESULTS
Subjects. The 10 healthy controls were well
matched with the 10 patients for age (ALS mean:
54.0 6 3.1 years; controls: mean 57.2 6 1.6 years;
P ¼ 0.373) and gender (ALS: 6 males; controls: 7
males; chi-square test: P ¼ 0.639). The mean dis-
ease duration in patients was 24.2 6 4.2 months.
The mean score on the revised ALS Functional
Rating Scale (ALS-FRS-R)26 was 36.6 6 1.5. None
of the 20 subjects reported adverse effects during
or after the experiments. The tDCS stimulation
was neither painful nor unpleasant for either the
healthy controls or the patients.
Maximal CMAP amplitude of the ADM was sim-
ilar in the patients and controls (11.1 6 0.8 mV
and 12.8 6 0.5 mV, respectively; P ¼ 0.330),
whereas CMAP amplitude of the APB was signiﬁ-
cantly lower in the patients than in controls (4.7 6
0.5 mV and 8.4 6 0.7 mV, respectively; P ¼ 0.035).
Neither the SI0.5mV (P ¼ 0.96) nor the SI1mV (P ¼
0.86) were signiﬁcantly different between patients
and controls.
Stimulus Intensity for Evoking MEPs of 0.5-mV Ampli-
tude. Using SI0.5mV as the dependent variable,
repeated-measures ANOVA revealed an effect of
time (F ¼ 15.38, P > 0.001), but not of tDCS dura-
tion. There was also a time  group interaction (F
¼ 6.01, P ¼ 0.006), indicating a difference in the
responsiveness to tDCS between groups. In addi-
tion, a signiﬁcant effect in the between-subject vari-
able group was found (F ¼ 7.265, P ¼ 0.015). Post
hoc paired t-tests demonstrated that SI0.5mV was
FIGURE 1. SI0.5mV stimulus intensities given as percentage of the pre-tDCS (0 minute) control values for healthy controls (a) and ALS
patients (b) at two time-points (5 and 20 minutes) after 7 (squares with solid line), 11 (triangles with dashed line), and 15 (diamonds
with dotted line) minutes of tDCS. The error bars signify the standard error of the mean.
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increased at 5 minutes after both 7 and 11 minutes
of tDCS (P ¼ 0.043 and 0.008, respectively) and at
20 minutes after 15 minutes of tDCS (P ¼ 0.040)
in healthy controls (Fig. 1a). In patients, the tDCS
effects on SI0.5mV were inconsistent. There was
only an increase in SI0.5mV after 7 minutes of tDCS
(P ¼ 0.02) but not after 11 or 15 minutes of tDCS
at 5 minutes after tDCS (Fig. 1b).
Single-Pulse MEPs. With regard to SI1mV MEP am-
plitude, repeated-measures ANOVA revealed no
signiﬁcant effect of tDCS duration or time, and no
interactions with group (Fig. 2). Obviously, post
hoc analysis did show a signiﬁcant decrease
in MEP size after 15 minutes in healthy controls
(Fig. 2a).
Intracortical Paired-Pulse Inhibition and
Facilitation. Figures 3 (SICI) and 4 (ICF) show
the paired-pulse data for healthy controls (Figs. 3a
and 4a) and ALS patients (Figs. 3b and 4b). The
baseline values of SICI and ICF were similar
between the groups (P ¼ 0.517 and 0.107, respec-
tively). Repeated-measures ANOVAs of the SICI
revealed a time  group interaction (F ¼ 4.80, P ¼
0.032), indicating that tDCS had different effects
on changes in SICI over time when comparing
patients and controls. Although not signiﬁcant for
any of the tDCS durations, a reduction in SICI in
healthy controls could be observed, whereas the
patients with ALS showed no change or only a
slight change in SICI. ANOVA of the ICF revealed
a signiﬁcant effect for the between-subject factor
group (F ¼ 5.805, P ¼ 0.027). On post hoc testing,
the ICF was higher overall in healthy controls com-
pared with the ALS patients (P < 0.01). No effect
of tDCS duration, time, or interactions with group
was found for the ICF.
DISCUSSION
Even after 15 minutes of stimulation, cathodal
tDCS does not induce a decrease of cortical excit-
ability in patients with ALS. This is in clear con-
trast to the results in healthy controls that do show
a decrease of cortical excitability with lengthening
of the stimulation duration. These results are not
encouraging for a potential therapeutic effect of
tDCS. However, they conﬁrm and extend the con-
clusion of the only other study that addressed the
effect of tDCS in ALS. In their investigation, Quar-
tarone et al. extensively discussed the potential
mechanisms that could underlie the lack of
responsiveness in the patient group, for example,
anatomical alterations of the motor cortex and
altered glutamate transmission.6 They considered
FIGURE 2. The single-pulse MEP amplitudes given as percentage of the pre-tDCS (0 minute) control values for healthy controls (a)
and ALS patients (b) at two time-points (5 and 20 minutes) after 7 (squares with solid line), 11 (triangles with dashed line), and 15
(diamonds with dotted line) minutes of tDCS. The error bars signify the standard error of the mean.
FIGURE 3. The short-interval intracortical inhibition (SICI) data given as ratio between the conditioned MEP and the unconditioned
MEP amplitudes for healthy controls (a) and ALS patients (b) before (0 minute) and at the two time-points (5 and 20 minutes) after 7
(squares with solid line), 11 (triangles with dashed line), and 15 (diamonds with dotted line) minutes of tDCS. The error bars signify
the standard error of the mean.
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that the threshold (duration of tDCS application)
for induction of the tDCS effects could be higher
in ALS patients compared with controls and that
this possible explanation could have been
excluded by applying longer duration tDCS proto-
cols. Our study, in which we doubled the stimula-
tion duration, now indeed excludes this possibility.
A ceiling effect of MEP amplitude related to the
loss of cortical neurons could be another explana-
tion, but this appears unlikely, because in the study
by Quartarone et al. the patients were in an earlier
stage of disease. Also, the use of riluzole could
have inﬂuenced the abnormal tDCS response,27
but this is unlikely. In the Quartarone et al. study
only 1 patient was on riluzole. The lack of tDCS af-
ter-effects in patients with ALS could also be
related to pathological changes in upper motor
neuron membrane function.
For now, we can only speculate on the implica-
tions of these results for the underlying pathologi-
cal upper motor neuron degeneration. Although
cathodal tDCS showed decreased relative glutamate
levels and gamma-aminobutyric acid in the motor
cortex in healthy controls,28 in this study we only
assessed the excitability with TMS. In other studies,
repetitive TMS (or theta burst stimulation) was
used to change the cortical excitability in ALS.29,30
In those earlier studies cortical excitability meas-
ures were not performed and, ultimately, 1 year of
treatment did not result in a reduced rate of dete-
rioration in ALS patients.
Our study supports the suggestion by Quartar-
one et al.,6 who indicated that an abnormal tDCS
effect might be a neurophysiological feature of
ALS. It raises the question of whether tDCS could
be a diagnostic tool for ALS or for the detection
of early upper motor neuron involvement in ALS.
However, the large variability in the TMS responses
with respect to the single MEP amplitudes, SICI
and ICF, as described earlier,31–33 which are not
explained by age, gender, or disease duration
(data not shown), will limit the diagnostic poten-
tial of the protocols applied.
We conclude that a single session of cathodal
tDCS does not produce an excitability shift in
patients with ALS. This is in contrast to the effect
of tDCS in healthy controls, where tDCS can
induce a decrease of cortical excitability. The vari-
ability in TMS effect that is found in patients with
ALS hampers its utility as a diagnostic tool and, if
diagnostic studies are considered, they should be
performed strictly according to the STARD crite-
ria.34 Our results are not encouraging for the ther-
apeutic effect of tDCS. However, further studies
are warranted, because, to date, only ‘‘one-session
tDCS’’ has been investigated, and repeated catho-
dal tDCS sessions may provide new insights.
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